Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Relation of lipid-lowering therapy to need for aortic valve replacement in patients with asymptomatic mild to moderate aortic stenosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Causes of Mortality in the Marfan Syndrome(from a Nationwide Register Study)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Survival in patients with scintigraphic evidence of pulmonary thromboembolism 12 weeks after double lung transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. High low-density lipoprotein levels and high risk of aortic stenosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

In this study, we aimed to determine if pretreatment low-density lipoprotein (LDL) levels and aortic stenosis (AS) severity alter the efficacy of lipid-lowering therapy on reducing aortic valve replacement (AVR). We used 1,687 patients with asymptomatic mild-to-moderate AS, who were randomly assigned (1:1) to 40/10 mg simvastatin/ezetimibe combination versus. placebo in the simvastatin and ezetimibe in aortic stenosis (SEAS) trial. Pretreatment LDL levels (>4 mmol/L) and peak aortic jet velocity (3 m/s) were used to partition study participants into 4 groups, which were followed for a primary endpoint of AVR. Cox regression with tests for interaction was used to study the effect of randomized treatment in each subgroup. During a median follow-up of 4.3 years (IQR 4.2 to 4.7 years; total 7,396 patient-years of follow-up), 478 (28%) patients underwent AVR and 146 (9%) died. A significant risk dependency was detected between simvastatin/ezetimibe combination, LDL levels and mild versus moderate AS on rates of AVR (p = 0.01 for interaction). In stratified analyses, randomized treatment, therefore, reduced the rate of AVR in patients with LDL levels >4 mmol and mild AS at baseline (HR 0.4; 95% CI: 0.2 to 0.9). There was no detectable effect of randomized treatment on the need for AVR in the 3 other participants subgroups. We conclude, that in a secondary analysis from a prospective randomized clinical trial, treatment with simvastatin/ezetimibe combination reduced the need for AVR in a subset of patients with mild AS and high pretreatment LDL levels (Unique identifier on clinicaltrials.gov: NCT00092677).

OriginalsprogEngelsk
TidsskriftThe American journal of cardiology
Vol/bind124
Udgave nummer11
Sider (fra-til)1736-1740
Antal sider5
ISSN0002-9149
DOI
StatusUdgivet - 1 dec. 2019

Bibliografisk note

Copyright © 2019 Elsevier Inc. All rights reserved.

ID: 58441048